Indegene’s Digital Rep Equivalence model drove growth for a mature cardiovascular drug nearing loss of exclusivity (LOE) at a rapidly growing company with over 1,000 employees focused on affordable patient care. Facing the challenge of maintaining $75 million in top-line revenue among covered HCPs while expanding 30% whitespace coverage for $100 million in savings, Indegene's software segmented HCPs with the highest engagement probability using digital affinity insights and Rx potential data. This targeted approach boosted reach, impact, and efficiency, delivering 10% gains without traditional reps.

Join for free to read